Drug Trial Radar · NCT07688213
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology. This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily. The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort. Up to 160 participants will be included in this study.
Conditions
- Dementia, Alzheimer's Type
- Alzheimer's Disease
Interventions
SAR448851Drug
Pharmaceutical form: Capsule Route of administration: Oral
PlaceboDrug
Pharmaceutical form: Capsule Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217Time frame: From baseline to Week 48
- Part B: Number of participants with treatment-emergent adverse events (TEAE), including ARIA-E and ARIA-H by brain MRI, laboratory assessments, vital sign measurements, ECGs and the C-SSRSTime frame: From Week 48 to Week 96
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
Healthy Brain Clinic- Site Number : 8400011
Long Beach, California · Recruiting
Oakland Clinical- Site Number : 8400010
Oakland, California · Recruiting
Aqualane Clinical Research- Site Number : 8400001
Naples, Florida · Recruiting
K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008
Orlando, Florida · Recruiting
Alzheimer's Research and Treatment Center - Stuart, FL- Site Number : 8400014
Stuart, Florida · Recruiting
Axiom Brain Health- Site Number : 8400019
Tampa, Florida · Recruiting
Charter Research - Lady Lake- Site Number : 8400004
The Villages, Florida · Recruiting
Alzheimer's Research and Treatment Center - Wellington- Site Number : 8400012
Wellington, Florida · Recruiting
Boston Center for Memory - Newton- Site Number : 8400007
Newton, Massachusetts · Recruiting
The Cognitive and Research Center of New Jersey - Springfield- Site Number : 8400005
Springfield, New Jersey · Recruiting
Summit Research Network - Portland - Northwest Vaughn Street- Site Number : 8400002
Portland, Oregon · Recruiting
Flourish Research - Keystone Clinical Studies- Site Number : 8400003
Plymouth Meeting, Pennsylvania · Recruiting
Rhode Island Mood & Memory Research Institute- Site Number : 8400015
East Providence, Rhode Island · Recruiting
Kerwin Medical Center- Site Number : 8400006
Dallas, Texas · Recruiting
Investigational Site Number : 0360001
Macquarie Park, New South Wales, Australia · Recruiting
Investigational Site Number : 0360003
Ivanhoe, Victoria, Australia · Recruiting
Investigational Site Number : 0360004
Melbourne, Victoria, Australia · Recruiting
Investigational Site Number : 1240001
Ottawa, Ontario, Canada · Recruiting
Investigational Site Number : 1240005
Toronto, Ontario, Canada · Recruiting
Investigational Site Number : 1240008
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 1560001
Beijing, China · Recruiting
Investigational Site Number : 2760003
Berlin, Germany · Recruiting
Investigational Site Number : 2760002
Cologne, Germany · Recruiting
Investigational Site Number : 7240001
Valencia, Spain · Recruiting
Investigational Site Number : 7240005
Zaragoza, Spain · Recruiting
Investigational Site Number : 7240008
Barcelona, Barcelona [Barcelona], Spain · Recruiting
Investigational Site Number : 7240006
Barcelona, Barcelona [Barcelona], Spain · Recruiting
Investigational Site Number : 7240004
Barcelona, Catalunya [Cataluña], Spain · Recruiting
Investigational Site Number : 7240003
Pozuelo de Alarcón, Madrid, Spain · Recruiting
Investigational Site Number : 8260002
London, Hammersmith and Fulham, United Kingdom · Recruiting
Investigational Site Number : 8260001
London, London, City of, United Kingdom · Recruiting
Investigational Site Number : 8260004
Bath, Somerset, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.